Nothing Special   »   [go: up one dir, main page]

Machado et al., 2001 - Google Patents

Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis

Machado et al., 2001

View HTML @Full View
Document ID
7928876012332111554
Author
Machado R
Santos R
Andrade S
Publication year
Publication venue
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

External Links

Snippet

Angiotensin-(1–7)[ANG-(1–7)], an endogenous bioactive peptide constituent of the renin- angiotensin system, acts as an inhibitory growth factor in vitro and in vivo. In this study, we evaluated whether the antiangiogenic effect of ANG-(1–7) in the mouse sponge model of …
Continue reading at journals.physiology.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides

Similar Documents

Publication Publication Date Title
Machado et al. Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis
Piliponsky et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis
Tallant et al. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle
Gomez-Arroyo et al. Iloprost reverses established fibrosis in experimental right ventricular failure
Klein et al. Angiotensin-(1–7) protects from experimental acute lung injury
Yamada et al. Converting enzyme determines plasma clearance of angiotensin-(1–7)
Handa et al. Angiotensin IV AT4-receptor system in the rat kidney
Tsuda Renin‐Angiotensin system and sympathetic neurotransmitter release in the central nervous system of hypertension
Vagnerova et al. Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase
Hua et al. Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5
Benderdour et al. Decreased cardiac mitochondrial NADP+-isocitrate dehydrogenase activity and expression: a marker of oxidative stress in hypertrophy development
Nielsen et al. The combination of Valsartan and Sacubitril in the treatment of hypertension and heart failure–an update
Gironacci et al. Neuromodulatory role of angiotensin-(1–7) in the central nervous system
Ullian et al. N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells
Ranga Rao et al. 4PBA strongly attenuates endoplasmic reticulum stress, fibrosis, and mitochondrial apoptosis markers in cyclosporine treated human gingival fibroblasts
Varagic et al. Predominance of AT1 blockade over Mas–mediated angiotensin-(1–7) mechanisms in the regulation of blood pressure and renin–angiotensin system in mRen2. Lewis rats
Cloutier et al. Pharmacological characterization of the cardiovascular responses elicited by kinin B1 and B2 receptor agonists in the spinal cord of streptozotocin‐diabetic rats
Clayton et al. CNS neuroplasticity and salt-sensitive hypertension induced by prior treatment with subpressor doses of ANG II or aldosterone
Arbin et al. Acute effect of the dual angiotensin‐converting enzyme and neutral endopeptidase 24‐11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat
O'Neill et al. Dietary sodium intake modulates renal excretory responses to intrarenal angiotensin (1–7) administration in anesthetized rats
Shah et al. Angiotensin-(1–7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger
Burns The emerging role of angiotensin-converting enzyme-2 in the kidney
Alzamora et al. Hypotensive effect of ANG II and ANG-(1–7) at the caudal ventrolateral medulla involves different mechanisms
Gu et al. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence
Abou Sawan et al. More than just a garbage can: emerging roles of the lysosome as an anabolic organelle in skeletal muscle